Business Insider10h
UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study
(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...
Biogen downgraded to Hold from Buy at Needham
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
Women's Health19d
5 Ways To Cover Unwanted Gray Hairs, According To Hairstylists
Finding a stray gray hair or two is an inevitable part of getting older. Here's why: Cells in your hair follicles called melanocytes produce the pigment that gives our hair its color and ...
ENDPOINTS NEWS19d
Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth
Bio­gen’s in­vestors are grow­ing rest­less. Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year ...
bnnbloomberg20d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
(Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance ...
The Boston Globe20d
Biogen raises forecast as Alzheimer’s drug Leqembi shows signs of growth
Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...
Morningstar20d
Biogen's stock hit by soft sales of Alzheimer's treatment
Biogen Inc.'s stock shed early gains to trade lower Wednesday after the biotech beat profit and revenue estimates for the third quarter and raised guidance. Mizuho said U.S. sales of the company's ...
Nasdaq20d
Biogen And Neomorph Collaborate To Develop Molecular Glue Degraders For Alzheimer's And More
(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...
Seeking Alpha20d
Biogen, Neomorph to collaborate on clinical candidates for Alzheimer's
Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...